Skip to main content
Top
Published in:

01-06-2019 | Tapentadol | Case report

Azathioprine

Herpes zoster resulting in postherpetic neuralgia: case report

Published in: Reactions Weekly | Issue 1/2019

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Witherspoon J, et al. Dupilumab off label benefits: A case study of severe atopic dermatitis and severe postherpetic neuralgia. Australasian Journal of Dermatology 60 (Suppl. 1): 99, May 2019. Available from: URL: http://doi.org/10.1111/ajd.13027 [abstract] - Australia Witherspoon J, et al. Dupilumab off label benefits: A case study of severe atopic dermatitis and severe postherpetic neuralgia. Australasian Journal of Dermatology 60 (Suppl. 1): 99, May 2019. Available from: URL: http://​doi.​org/​10.​1111/​ajd.​13027 [abstract] - Australia
Metadata
Title
Azathioprine
Herpes zoster resulting in postherpetic neuralgia: case report
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2019
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-63615-7